Hot Life Science Investor Mandate 1: Canadian VC with New Fund Seeking Early Stage Life Companies throughout the US and Canada

20 Nov

A Canadian VC firm is currently investing from a second fund raised in 2014, with a closing target of $150 million.  The fund will make equity investments in early-stage life science companies based in Canada and the USA.  The firm prefers to lead or co-lead investments.  Initial investments will typically be of about $5 million, with capital reserved for potential follow-on investments of up to $15 million total per opportunity.  The firm is likely to make 10-12 investments over the fund’s lifetime.

The firm will make about 75% of its allocations in the therapeutics sector, with the remainder invested in diagnostics, medical devices, and/or tools or healthcare IT.  The firm prefers to invest in early-stage opportunities; in the therapeutics sector, investments may be made in companies with a lead product 12-18 months prior to IND.  The fund is generally agnostic in terms of technological field and indication area, but is less likely to invest in products targeting CNS disorders and pain.

The firm only invests in those therapeutic companies that have identified a lead product candidate.  About two-thirds of investments will be made in Canada-based life science companies, with half of the Canadian portfolio consisting of Quebec-based companies; the remaining one-third of the fund will be invested in USA-based companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: